http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6346524-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395
filingDate 2000-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2002-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7032c2e2423bbe8b2e509eb284572b76
publicationDate 2002-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-6346524-B1
titleOfInvention Cancer treatment with temozolomide
abstract A method for treating a patient afflicted with cancer is provided, in which temozolomide is administered to the patient for at least two cycles of a cyclical dosing schedule, wherein each cycle has a dosing period of 5 to 25 days, in which temozolomide is administered daily, at a dose of 40 to 150 mg/m2/day, followed by a rest period of 5 to 14 days in which temozolomide is not administered.Also provided is a medical kit for administering temozolomide, having printed instructions for administering temozolomide according to the cyclical dosing schedule set forth above, and a supply of temozolomide in dosage units for at least one cycle, wherein each dosage unit contains 5 to 250 mg of temozolomide and a pharmaceutically acceptable carrier.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006074073-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007111979-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010240723-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003229112-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006229456-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018167627-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004223951-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006100188-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004105906-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7446209-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010099697-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7087751-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11147810-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9561214-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009247598-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2409700-A1
priorityDate 1999-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2184545-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12049214
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506968
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3100
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127548128
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419533788
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5394
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226414680
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID698135
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3958
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8980
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396518
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396519
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556073
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395857
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129978914
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226491690
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID142422867
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4595
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226407194
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534943
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127741278

Total number of triples: 50.